Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Chest MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Centers for disease control and prevention https://www.cdc.gov/infectioncontrol/guidelines/mdro/. updated February 2017 Accessed July 7, 2022.
Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report Bethesda, Maryland ©2021 Cystic Fibrosis Foundation.
- The impact of CFTR modulator therapies on CF airway microbiology.J Cyst Fibros. 2020; 19: 359-364
- Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy.Pediatr Pulmonol. 2019; 54: S18-S26
- Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.Am J Respir Crit Care Med. 2017; 195: 1617-1628
- Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.Ann Am Thorac Soc. 2020; 17: 212-220
- State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary.Pediatr Pulmonol. 2021; 56: 1825-1837
- Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.Cochrane Database of Systematic Reviews. 2018;
- Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.Clin Ther. 2016; 38: 2204-2226
- Inhaled Antibiotics for Gram-Negative Respiratory Infections.Clinical microbiology reviews. 2016; 29: 581-632
- New β-Lactam-β-Lactamase Inhibitor Combinations.Clin Microbiol Rev. 2020; 34
- Enhanced drug metabolism in young children with cystic fibrosis.Arch Dis Child. 1997; 77: 239-241
- Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.Ann Pharmacother. 1993; 27: 74-79
- Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.Drugs. 1988; 35: 542-578
- State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.Pediatr Pulmonol. 2020; 55: 33-57
- Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins latest update.Pediatr Pulmonol. 2021; 56: 1784-1788
- Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.Clin Pharmacokinet. 2021; 60: 409-445
- Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.P T. 2011; 36: 723-763
- Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.Antimicrob Agents Chemother. 2017; 61
- Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data.Front Pediatr. 2020; 8: 173
- Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.Open Forum Infect Dis. 2018; 5: ofy158
- Ceftazidime-avibactam for the treatment of multidrug resistant Burkholderia cepacia complex in a pediatric cystic fibrosis patient.Pediatr Pulmonol. 2020; 55: 283-284
- In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.Diagn Microbiol Infect Dis. 2021; 99: 115204
- Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series.J Antimicrob Chemother. 2019; 74: 1425-1429
- Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients.JAC Antimicrob Resist. 2021; 3: dlab126
- Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.Antimicrob Agents Chemother. 2018; 62
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.Clin Infect Dis. 2017; 65: 110-120
- Ceftolozane/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa.IDCases. 2020; 21: e00830
- Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency.Respir Med Case Rep. 2018; 23: 8-9
- Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.Pharmacotherapy. 2016; 36: e154-e159
- Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem-vaborbactam and cefiderocol.Pediatr Pulmonol. 2021; 56: 3059-3061
- Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.J Clin Microbiol. 2019; 57
- Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.Sci Rep. 2020; 10: 928
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019; 79: 271-289
- Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?.Microb Drug Resist. 2021 Dec; 27: 1726-1732
- Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.Clin Infect Dis. 2021; 73: e1754-e1757
- Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis.J Cyst Fibros. 2012; 11: 288-292
- Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.Lancet. 2005; 366: 463-471
- Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.Lancet Infect Dis. 2021; 21: 597-598
- Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.Int J Antimicrob Agents. 2018; 52: 697-701
- Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis.J Cyst Fibros. 2018; 17: e25-e31
- Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis.Pediatr Pulmonol. 2020; 55: 3337-3342
- Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient.J Pediatr Pharmacol Ther. 2014; 19: 135-140
- Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.Commun Biol. 2020; 3: 599
- Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities.Ann Am Thorac Soc. 2019; 16: 534-539
- Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2020; 64
- Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.Journal of Cystic Fibrosis. 2019; 18: 357-363
- A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.J Cyst Fibros. 2016; 15: 495-502
- Drug development pipeline: inhaled levofloxacin (Quinsair).(Available at:) (Accessed July 7 ,2022)
- Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections.J Cyst Fibros. 2019; 18: 714-720
- Beyond antibiotics for pulmonary nontuberculous mycobacterial disease.Curr Opin Pulm Med. 2020; 26: 260-266
- Nitric oxide synthase in innate and adaptive immunity: an update.Trends Immunol. 2015; 36: 161-178
- Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis.J Pathol. 1998; 184: 323-331
- Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis.Immunity. 2003; 18: 619-630
- Antibacterial activity of high-dose nitric oxide against pulmonary Mycobacterium abscessus disease.Access Microbiol. 2020; 2 (acmi000154)
- Non-nuberculous mycobacteria infection treated with intermittently inhaled high-dose nitric oxide.BMJ Case Rep. 2021; 14
- Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients.Pediatr Infect Dis J. 2018; 37: 336-338
- Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection.J Cyst Fibros. 2020; 19: 225-231
Cystic Fibrosis Foundation https://apps.cff.org/Trials/Pipeline/details/10122/Inhaled-Nitric-Oxide-Thiolanox. Accessed July 7, 2022.
- Inhaled granulocyte-macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis.Eur Respir J. 2018; 51
Cystic Fibrosis Foundation. https://apps.cff.org/Trials/Pipeline/details/10165/Inhaled-Molgramostim. Accessed July 7, 2022.
- Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium.Pathobiology. 1991; 59: 3-10
- Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections.Sci Transl Med. 2018; 10
- The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity.J Clin Invest. 2007; 117: 877-888
- Gallium Compounds Exhibit Potential as New Therapeutic Agents against Mycobacterium abscessus.Antimicrob Agents Chemother. 2015; 59: 4826-4834
- Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria.Cell Host & Microbe. 2019; 25: 219-232
- Virioplankton: viruses in aquatic ecosystems.Microbiology and molecular biology reviews : MMBR. 2000; 64: 69-114
- Biogeography and individuality shape function in the human skin metagenome.Nature. 2014; 514: 59-64
- Viruses in the faecal microbiota of monozygotic twins and their mothers.Nature. 2010; 466: 334-338
- Bacteriophage Clinical Use as Antibacterial "Drugs": Utility and Precedent.Microbiol Spectr. 2017; 5
- The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole.Viruses. 2019; 11
- Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus.Nat Med. 2019; 25: 730-733
- Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?.Clinical Therapeutics. 2020; 42: 1659-1680
- The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams.Clin Infect Dis. 2017; 64: 1582-1588
- Bacteriophage therapy for infections in CF.Pediatr Pulmonol. 2021; 56 (S4–s9)
- Resistance Evolution against Phage Combinations Depends on the Timing and Order of Exposure.mBio. 2019 Sep 24; 10 (e01652–19)
- Reduced fecundity is the cost of cheating in RNA virus phi6.Proc Biol Sci. 2004; 271: 2275-2282
- Bacteriophage resistance mechanisms.Nat Rev Microbiol. 2010; 8: 317-327
- Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa.Sci Rep. 2016; 6: 26717
- Phage treatment of an aortic graft infected with Pseudomonas aeruginosa.Evol Med Public Health. 2018; 2018: 60-66
- Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection.Nat Med. 2021; 27: 1357-1361
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
